NO20014895L - Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate - Google Patents

Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate

Info

Publication number
NO20014895L
NO20014895L NO20014895A NO20014895A NO20014895L NO 20014895 L NO20014895 L NO 20014895L NO 20014895 A NO20014895 A NO 20014895A NO 20014895 A NO20014895 A NO 20014895A NO 20014895 L NO20014895 L NO 20014895L
Authority
NO
Norway
Prior art keywords
bisphosphonate
additive
pharmaceutical formulation
provides increased
formulation including
Prior art date
Application number
NO20014895A
Other languages
Norwegian (no)
Other versions
NO20014895D0 (en
Inventor
Lennart Lindfors
Jan-Erik Loefroth
Sven Sjoegren
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20014895D0 publication Critical patent/NO20014895D0/en
Publication of NO20014895L publication Critical patent/NO20014895L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20014895A 1999-04-09 2001-10-08 Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate NO20014895L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (en) 1999-04-09 1999-04-09 New improved formulation
PCT/SE2000/000664 WO2000061111A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate

Publications (2)

Publication Number Publication Date
NO20014895D0 NO20014895D0 (en) 2001-10-08
NO20014895L true NO20014895L (en) 2001-12-10

Family

ID=20415159

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014895A NO20014895L (en) 1999-04-09 2001-10-08 Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate

Country Status (11)

Country Link
EP (1) EP1171097A1 (en)
JP (1) JP2002541185A (en)
KR (1) KR20010104389A (en)
AU (1) AU4161900A (en)
CA (1) CA2364659A1 (en)
IL (1) IL145506A0 (en)
NO (1) NO20014895L (en)
NZ (1) NZ514478A (en)
SE (1) SE9901272D0 (en)
WO (1) WO2000061111A1 (en)
ZA (1) ZA200108260B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CN1446093A (en) * 2000-04-07 2003-10-01 得克萨斯系统大学董事会 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
EP1284754B1 (en) * 2000-05-05 2006-01-04 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
JP4354698B2 (en) * 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク Bisphosphonate delivery composition
EP1401406A2 (en) 2001-07-02 2004-03-31 Merrion Research I Limited Delivery of a bioactive material
KR20120065435A (en) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 Bisphosphonic acid for the treatment and prevention of osteoporosis
SG174628A1 (en) 2002-12-20 2011-10-28 Hoffmann La Roche High dose ibandronate formulation
PT1583768E (en) * 2003-01-17 2008-09-11 Teva Pharma Method for reducing the iron content of risedronate sodium
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2004110458A1 (en) * 2003-05-16 2004-12-23 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
SI1753395T1 (en) * 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
KR100815040B1 (en) * 2005-01-31 2008-03-18 주식회사종근당 Pharmaceutical compositions containing bisphosphonate for improving oral absorption
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
ES2426445T3 (en) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
TW200950801A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of peptides and processes of preparation thereof
AU2009274229B2 (en) 2008-07-21 2013-08-22 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
KR101631243B1 (en) * 2009-05-13 2016-06-17 신일제약주식회사 Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same
PT2459176T (en) 2009-07-31 2017-12-11 Gruenenthal Gmbh Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
FR2954320B1 (en) 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR20140026354A (en) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 Pharmaceutical compositions of iron for oral administration
KR20120105738A (en) * 2011-03-16 2012-09-26 현대약품 주식회사 An enteric-coated oral formulation
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US20180161401A1 (en) * 2015-07-06 2018-06-14 Zheng Xin Dong Novel Formulations of PTHrP Analogue
EP3455229B1 (en) * 2016-05-13 2021-03-24 Thar Pharma LLC Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN112972400A (en) * 2021-03-09 2021-06-18 华侨大学 Rapidly disintegrable minodronic acid granules and preparation method thereof
KR20240013402A (en) * 2022-07-22 2024-01-30 주식회사 아이큐어비앤피 Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
SE501389C2 (en) * 1992-04-24 1995-01-30 Leiras Oy Pharmaceutical preparation and process for its preparation
CZ287984B6 (en) * 1993-05-15 2001-03-14 Roche Diagnostics Gmbh Tablet with enhanced biological availability of active substance i.e. clodronic acid and process for preparing thereof
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
FI109088B (en) * 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
SE9703691D0 (en) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
AU4161900A (en) 2000-11-14
EP1171097A1 (en) 2002-01-16
WO2000061111A1 (en) 2000-10-19
ZA200108260B (en) 2003-03-26
NZ514478A (en) 2004-01-30
CA2364659A1 (en) 2000-10-19
JP2002541185A (en) 2002-12-03
NO20014895D0 (en) 2001-10-08
SE9901272D0 (en) 1999-04-09
KR20010104389A (en) 2001-11-24
IL145506A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
NO20014895D0 (en) Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate
NO20040564L (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
NO20043702L (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
NO20016277D0 (en) Systems and methods for aerolizing pharmaceutical formulations
DK1020462T3 (en) Heterocyclic compounds and anti-tumor agents containing these as active ingredient
IL166232A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
DK1498411T3 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
NO20033384D0 (en) Pharmaceutical formulation
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
NO20033785D0 (en) Pharmaceutical formulation
GB0118689D0 (en) Pharmaceutical formulation
NO20035627D0 (en) Pharmaceutical formulation
NO20006646L (en) Amino acid derivatives and drugs containing the same as active ingredient
ID30032A (en) PHARMACEUTICAL FORMULATION
DK0994697T3 (en) Rapamycin formulations for oral administration
AR025867A1 (en) PHARMACEUTICAL PORTASDORA FORMULATION
NO20004816D0 (en) New pharmaceutical formulation
GB0201607D0 (en) Formulation for the administration of medicinal substances
GB0104749D0 (en) Pharmaceutical formulation
NO20041236L (en) Pharmaceutical Formulation
AU2003238900A8 (en) Pharmaceutical formulation
SE9803952D0 (en) Pharmaceutical formulation
PT102453B (en) Formulation of a cephalosporinic compound and tablet comprising the said compound and a water-soluble solution
SI1124539T1 (en) Pharmaceutical formulation comprising omeprazole
SE0102572D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application